(Q44431114)

English

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma

scientific article published in May 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 December 2017

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma (English)

1 reference

Europe PubMed Central

2 December 2017

author name string

Hess G

1

1 reference

Europe PubMed Central

2 December 2017

Flohr T

2

1 reference

Europe PubMed Central

2 December 2017

Huber C

3

1 reference

Europe PubMed Central

2 December 2017

Kolbe K

4

1 reference

Europe PubMed Central

2 December 2017

Derigs HG

5

1 reference

Europe PubMed Central

2 December 2017

Fischer T

6

1 reference

Europe PubMed Central

2 December 2017

language of work or name

0 references

publication date

1 May 2003

1 reference

Europe PubMed Central

2 December 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

2 December 2017

31

1 reference

Europe PubMed Central

2 December 2017

9

1 reference

Europe PubMed Central

2 December 2017

775-782

1 reference

Europe PubMed Central

2 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1703925

0 references

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Rituximab: enhancing stem cell transplantation in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Fatal cytomegalovirus interstitial pneumonia following autologous peripheral blood stem cell transplantation. Fukuoka Bone Marrow Transplantation Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

21 January 2018

Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703925

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1703925

1 reference

Europe PubMed Central

2 December 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

2 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44431114&oldid=2023228940"